# Breast Cancer Epidemiology and Early Detection

Dr Seyyaedeh Setareh Roudbari Breast Surgeon Rasht Ghaem int Hospital

## Introduction

- Breast cancer is the most frequently diagnosed cancer in women worldwide with 2.26 million new cases in 2020.
- Besides being the most common, breast cancer is also the <u>leading cause</u> of cancer death in women worldwide.

#### Although incidence rates were the highest in developed regions, the countries in Asia and Africa shared 63% of total <u>deaths</u> in 2020.

 Most women who develop breast cancer in a high-income country will survive; the opposite is <u>true</u> for women in most lowincome and many middle-income countries.  In 2020 breast cancer mortality-to-incidence ratio (MIR) as a representative indicator of 5year survival rates was 0.30 globally.

- In locations with developed health care (Hong-Kong, Singapore, Turkey) the 5-year survival was 89.6% for localized and 75.4% for regional cancer.
- In less developed countries (Costa Rica, India, Philippines, Saudi Arabia, Thailand) the survival rates were 76.3% and 47.4% for localized and regional breast cancer respectively.

- Breast cancer <u>incidence</u> and <u>death rates</u> have increased over the last three decades.
- Between 1990 and 2016 breast cancer incidence has more than doubled in 60/102 countries (Afghanistan, Philippines, Brazil, Argentina), whereas deaths have doubled in 43/102 countries (Yemen, Paraguay, Libya, Saudi Arabia).

 Current projections indicate that by 2030 the worldwide number of <u>new cases</u> diagnosed reach 2.7 million <u>annually</u>, while the <u>number</u> of deaths 0.87 million.  In low- and medium - income countries, the breast cancer incidence is expected to increase further due to the westernization of lifestyles (delayed pregnancies, reduced breastfeeding, low age at menarche, lack of physical activity, and poor diet), better cancer registration, and cancer detection

- The incidence of breast cancer by age and geographic distribution shows that in developing countries this incidence is 23% in young adults (15-49 years) versus 10% in developed countries.
- In menopausal females (>50 years) the incidence is <u>28</u>% in developing countries versus 39% in developed countries.
- Menopausal females from developed countries have a greater incidence of cancer.

#### **Breast Cancer Epidemiology in IRAN**

- Akbari et al. reported that the mean age for breast cancer in Iran was <u>5 years earlier</u> in Iranian women compared to women from developed countries.
- According to the national cancer registry database, 57.6% of breast cancer cases were seen in women <50 years of age.</li>

Akbari ME, Khayamzadeh M, Khoshnevis S, Nafisi N, Akbari A. Five and ten years survival in breast cancer patients mastectomies vs. breast conserving surgeries personal experience. *Iran J Cancer Prev.* 2012;1(2):53-6.

## Age and gender

- In Iran, the mean age at breast cancer diagnosis is 47.95 54.6 years.
- The most common patient age group is 41-49 years.
- The rate of breast cancer in iranian men is
  2.8%, which is <u>higher than</u> other parts of the world.

Table 3. Age distribution of breast cancer patients according to age (years) in Iran.

Age (years)	Number	Percent
<30	39	6.4
30-34	42	6.9
35-39	89	14.5
40-44	114	18.6
45-49	125	20.4
50-54	83	13.5
55-59	59	9.6
60-64	23	3.8
65-69	22	3.6
70-74	17	2.8

## **Risk Factors of Breast Cancer**

Table 1. Modifiable and non-modifiable risk factors of breast cancer.

\_

Non-Modifiable Factors Modifiable Factors		
Female sex	Hormonal replacement therapy	
Older age	Diethylstilbestrol	
Family history (of breast or ovarian cancer)	Physical activity	
Genetic mutations	Overweight/obesity	
Race/ethnicity	Alcohol intake	
Pregnancy and breastfeeding	Smoking	
Menstrual period and menopause	Insufficient vitamin supplementation	
Density of breast tissue	Excessive exposure to artificial light	
Previous history of breast cancer	Intake of processed food	
Non-cancerous breast diseases	Exposure to chemicals	
Previous radiation therapy	Other drugs	

# **Family History**

- 13–19% of patients diagnosed with breast cancer report a <u>first-degree</u> relative affected by the same condition.
- Breast cancer risk significantly increases with an increasing number of first-degree relatives affected.
- Risk might be even higher when the affected relatives are <u>under 50 years old</u>.

#### **Reproductive History**

- Numerous studies confirmed a <u>strict</u> relationship between exposure to endogenous hormones and excessive risk of breast cancer in females.
- Occurrence of specific events such as pregnancy, breastfeeding, first menstruation, and menopause along with their duration and the concomitant hormonal imbalance, are crucial in carcinogenic events in the breast microenvironment.

### **Reproductive History**

 First full-term pregnancy at an early age (especially in the <u>early twenties</u>) along with a subsequently increasing number of births are associated with a reduced risk of breast cancer.

### **Density of Breast Tissue**

 Greater breast tissue density correlates with the greater breast cancer risk; this trend is observed both in premenopausal and postmenopausal females.

#### **Exposure to Artificial Light**

- Artificial light at night (ALAN) has been recently linked to increased breast cancer risk.
- The probable causation might be a disrupted melatonin rhythm and subsequent epigenetic alterations.
- Increased exposure to ALAN is associated with a significantly greater risk of breast cancer compared to individuals with lowered ALAN exposure.

### **Chosen Drugs**

- The intake of diethylstilbestrol during pregnancy is associated with an increased risk of breast cancer not only in mothers but also in the offspring.
- Numerous researches indicate that females who use hormonal replacement therapy (HRT) especially longer than 5 or 7 years are also at increased risk of breast cancer.

# Breast cancer early detection

### Introduction

 Previous studies have suggested that early breast cancer detection with suitable treatment could <u>reduce</u> breast cancer death rates <u>significantly</u> in the long-term.

- Mammography is the current standard breast screening technique, but it is less effective for subjects under 40 years old and dense breasts, less sensitive to small tumors.
- Ultrasound has been applied as an <u>additional</u> medical imaging tool for mammography.

- Magnetic resonance imaging (MRI) has the ability to detect small lesions that cannot be detected by mammography, however, it is also expensive and has low specificity, which can lead to <u>overdiagnosis</u>.
- Positron emission tomography (PET) is the most accurate method for visualizing the spread of tumors or their response to therapy.

 Microwave imaging (MI) techniques have been recently recommended as a safe and low-cost alternative approach to mammography for diagnosing breast cancer.

# Mammography

- Annual mammograms are recommended for females beginning at age 40, and they are particularly beneficial for females aged between the ages of 40 and 74.
- Contrast-enhanced (CE) digital mammography that uses intravenous contrast injections, generates higher sensitivity compared to mammography.

# Ultrasound

- Breast ultrasonography is a cost-effective and widely available screening tool.
- Breast ultrasonography helps to:
- 1. identify cysts and solid masses
- 2. increases the cancer detection rates but less efficient compared to mammography

# Ultrasound

 Breast ultrasonography has been recommended as a <u>supplement</u> to mammography for subjects with <u>high breast cancer risk</u>, <u>pregnant women</u> and subjects who <u>cannot to have</u> <u>mammography</u>.

### MRI

 Breast MRI has been recommended for subjects with high breast cancer risk, but it has not been recommended for the general population due to its high false-positive rate, high cost, time consumption, the need for experienced radiologists.

# Microwave Breast Imaging (MI)

- MI techniques can be grouped as passive and active, and active approaches can be subgrouped into two major groups:
- 1. microwave tomographic
- 2. radar-based MI

#### Passive MI uses radiometry to measure the temperature differences between normal and malignant tissues.

 Active MI measures the dielectric properties (DPs) contrast between healthy tissue and malignant tissue.

## **Microwave Imaging**

- MI has the potential to become a low risk alternative or clinical complement to conventional mammography for diagnosing breast cancer.
- MI and biosensor techniques are still not mature and many challenges need to be solved before they can be implemented for clinical trials.

